Microdose tirzepatide: the clinical case, and the legal one
"Microdose" tirzepatide means roughly 1 mg per week — below every dose studied in SURMOUNT, the trial programme that established tirzepatide's efficacy (5, 10 and 15 mg). It has a genuine clinical rationale for some patients. It is also the regulatory mechanism that lets 503A pharmacies keep compounding tirzepatide at all, now that enforcement discretion has ended. Both of those things are true at once.
Two true things at once
"Microdosing" is marketed as a gentler, cheaper, smarter way to take a GLP-1. Two things are true about it at once, and honest coverage has to hold both.
It has a real clinical rationale for some patients — people who cannot tolerate full-dose escalation, people maintaining after reaching goal weight, and people for whom cost is the binding constraint. A clinician-directed low dose is a legitimate choice for them.
And it is also a regulatory workaround. A dose that is not "the same, similar, or easily substitutable" for an approved strength is a dose that falls outside the "essentially a copy" prohibition — which is the only reason a 503A pharmacy can still compound these molecules at all. The industry-wide pivot to "personalized" and "microdose" dosing tracks the end of enforcement discretion in 2025 almost exactly. That timing is not a coincidence, and no one selling it will tell you so.
What follows for a patient: ask why your specific dose was chosen, and whether the answer is about your body or about the pharmacy's legal position. Expect a smaller effect than the trial headlines. And be aware that evidence for below-label regimens is thin — they have not been through anything resembling SURMOUNT.
How far below the trial doses it sits
| Period | Dose | Note |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Starting dose. Not intended for weight loss — this is a tolerance-building dose. |
| Weeks 5–8 | 5 mg | First therapeutic dose. |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose. |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose. |
1. The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose that is not intended to produce weight loss. Ask what you will pay at 10 mg, and compare that number.
2. A "microdose" of roughly 1 mg/week sits below every dose studied in SURMOUNT. The trials that established tirzepatide's efficacy used 5, 10 and 15 mg. A 1 mg microdose is not a discounted version of that result; it is a different product with a smaller expected effect and no equivalent trial evidence behind it.
What the evidence actually supports
SURMOUNT-1 studied 5 mg, 10 mg and 15 mg, producing mean weight reductions of 15.0%, 19.5% and 20.9% over 72 weeks. A 1 mg microdose has no equivalent trial behind it, and should be expected to produce a smaller effect. That is not a criticism of microdosing — it is arithmetic. Anyone presenting a microdose programme as a cheaper route to the SURMOUNT headline number is misleading you.
| Trial | Arm | Result | Duration | Comparator | Source |
|---|---|---|---|---|---|
| SURMOUNT-1 | Tirzepatide 15 mg | −20.9% | 72 weeks | Placebo −3.1% | NEJM 2022 (Jastreboff et al.) |
| SURMOUNT-1 | Tirzepatide 10 mg | −19.5% | 72 weeks | NEJM 2022 | |
| SURMOUNT-1 | Tirzepatide 5 mg | −15.0% | 72 weeks | NEJM 2022 | |
| SURMOUNT-5 | Tirzepatide (max tolerated) | −20.2% | 72 weeks | vs semaglutide −13.7% | NEJM 2025 (Aronne et al.) |
| STEP 1 | Semaglutide 2.4 mg | −14.9% | 68 weeks | Placebo −2.4% | NEJM 2021 (Wilding et al.) |
| STEP 8 | Semaglutide 2.4 mg | −15.8% | 68 weeks | vs liraglutide 3.0 mg −6.4% | JAMA 2022 (Rubino et al.) |
| SCALE | Liraglutide 3.0 mg | −8.0% | 56 weeks | Placebo −2.6% | NEJM 2015 |
| SELECT | Semaglutide 2.4 mg | 20% MACE reduction | ~40 months | Cardiovascular outcomes | NEJM 2023 |
Five questions to ask before you enrol
- Why was this specific dose chosen for me, clinically?
- Is the dose selected partly to keep the product outside the FDA's 'essentially a copy' rule?
- What is the exact salt form and concentration?
- What will I pay if I escalate to a therapeutic dose?
- What happens to my supply if the pharmacy receives an FDA or manufacturer notice?
Frequently asked questions
Is microdose tirzepatide as effective as a full dose?
No. The trials that established tirzepatide's efficacy used 5-15 mg. A roughly 1 mg microdose sits below all of them and has no equivalent trial evidence. Expect a smaller effect.
Why did so many providers suddenly start offering microdosing?
The timing tracks the end of FDA enforcement discretion in early 2025 almost exactly. A dose that is not 'the same, similar, or easily substitutable' for an approved strength falls outside the 'essentially a copy' prohibition — which is the remaining route for a 503A pharmacy to compound these molecules. It is a legal mechanism at least as much as a clinical one, and no one selling it will tell you that.
Is microdosing safer?
Lower doses generally cause milder gastrointestinal effects, but they do not remove the class boxed warning or the contraindications, and the compounded product itself is not FDA-approved. Any low-dose regimen should be clinician-directed.
Sources
- U.S. Food and Drug Administration — labels and safety communications.
- Peer-reviewed clinical trials cited above.
- Our methodology and medical review policy.